SCHEMBL6654583

SCHEMBL6654583

CCCCCCN1CCC(CCC)(c2cccc(O)c2)CC1

nearest known ligand 0.66

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 1/20 0.66
OPRM1 P35372 1/20 0.61
ACHE P22303 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6653321 0.85 DRD3 (0.48) DRD3OPRM1
SCHEMBL6655150 0.85 DRD3 (0.69) DRD3OPRM1ACHE
SCHEMBL11637435 0.84 ACHE (0.61) DRD3ACHE
SCHEMBL27304227 0.81 OPRD1 (0.57) DRD3OPRM1
SCHEMBL11814580 0.80 DRD3 (1.00) DRD3OPRM1
SCHEMBL11813871 0.80 DRD3 (1.00) DRD3OPRM1
Profadol SCHEMBL160670 0.79 ACHE (0.66) OPRM1ACHE
Bromide SCHEMBL11818169 0.79 DRD3 (0.98) DRD3OPRM1
Bromide SCHEMBL11812525 0.79 DRD3 (0.98) DRD3OPRM1
SCHEMBL6658571 0.78 DRD3 (0.45) DRD3OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1077940-B1 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES PFIZER (US) 2004-07-14 EP disclosed
US-6610711-B2 4-phenylpiperidines for the treatment of pruritic dermatoses PFIZER INC. 2003-08-26 US disclosed
US-20030078282-A1 Novel 4-phenylpiperidines for the treatment of pruritic dermatoses PFIZER INC. 2003-04-24 US disclosed
EP-1077940-A1 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES PFIZER INC. (US) 2001-02-28 EP disclosed
WO-1999059971-A1 NOVEL 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES PFIZER INC. (US) 1999-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078282-A1 Novel 4-phenylpiperidines for the treatment of pruritic dermatoses HRH2, HRH4, HRH1 DRD3 101/4885OPRM1 409/4885ACHE 3045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.